Rockland Trust Co. Purchases 334 Shares of Edwards Lifesciences Co. (NYSE:EW)

Rockland Trust Co. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,353 shares of the medical research company’s stock after buying an additional 334 shares during the quarter. Rockland Trust Co.’s holdings in Edwards Lifesciences were worth $322,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after buying an additional 2,606,950 shares during the period. Nordea Investment Management AB raised its holdings in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new stake in Edwards Lifesciences in the third quarter valued at $39,628,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EW. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Truist Financial restated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Piper Sandler reduced their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $79.40.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,500 shares of company stock worth $2,160,800 over the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.1 %

Edwards Lifesciences stock opened at $70.29 on Thursday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a fifty day simple moving average of $71.82 and a two-hundred day simple moving average of $71.62. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $41.46 billion, a price-to-earnings ratio of 10.14, a PEG ratio of 3.61 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 EPS. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.